Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? 

MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous Nephropathy

Obinutuzumab demonstrated superior complete remission rates at 2 years compared with tacrolimus in primary membranous nephropathy in the phase 3 MAJESTY trial, supporting a potential new B-cell–targeted standard of care.

Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or Overweight

In adults with moderate-to-severe plaque psoriasis and obesity or overweight, combination therapy with ixekizumab and tirzepatide achieved superior skin clearance and weight reduction at 36 weeks compared with ixekizumab alone.

AREXVY Vaccine Reduces Hospitalization, Major Adverse Cardiovascular Events in RSV

Real-world data from over 2.5 million patients showed GSK’s AREXVY vaccine was 75.6% effective against RSV-related hospitalization, with additional signals suggesting reduced in-hospital major adverse cardiovascular events in older adults.

COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRD

COMP360 synthetic psilocybin met the primary endpoint in its second phase 3 trial in treatment-resistant depression, demonstrating significant symptom reduction at week 6 versus low-dose control and advancing toward potential regulatory submission.

Thykamine Shows Disease-Modifying Potential in MASH Using Liver-on-a-Chip Platform

Preclinical data using a human liver-on-a-chip model suggest Thykamine may exert dose-dependent antifibrotic and anti-inflammatory effects in MASH, supporting further translational development.

Articles

Multiple late-breaking data sets highlight advances across immunology, metabolic disease, vaccines, neuropsychiatry, and liver fibrosis. In primary membranous nephropathy, B-cell depletion with obinutuzumab produced higher 2-year complete remission than tacrolimus, suggesting a practice-shifting option. For patients with plaque psoriasis plus obesity/overweight, ixekizumab combined with tirzepatide improved PASI responses and weight loss versus ixekizumab alone. Real-world effectiveness analyses support AREXVY in preventing RSV hospitalization and suggest fewer in-hospital MACE. Synthetic psilocybin (COMP360) achieved a second phase 3 primary endpoint in TRD. Liver-on-a-chip work indicates antifibrotic potential for Thykamine in MASH.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatology

HCPLive 5 Stories in Under 5: Week of 02/15

Mary K Roberts, PhD is a Post Doctoral Researcher at the Leverhulme Centre for Demographic Science at the University of Oxford.

Donor–Recipient Closeness and Perceived Life Extension Drive Living Kidney Donation Decisions

New data from a US-based survey suggest the closeness of the donor–recipient relationship and perceived health benefits for the recipient may be strong motivators for living donors, with insights that could inform counseling strategies in transplant programs.

There are 90,000 individuals awaiting kidney transplants in the US alone, making up 86-87% of the national transplant waiting list. In 2025, the US achieved a record of organ transplants, with a 3% increase in individuals becoming living organ donors, according to data from the Organ Procurement and Transplantation Network. Living donor kidney transplantation has been associated with superior graft survival and improved patient outcomes for patients with ESKD, rates of living donation remain low.

“One of the major gaps in the living donation literature that we were really focused on was that most research examines barriers from the patient or provider perspective,” Mary K Roberts, PhD, Post Doctoral Researcher at the Leverhulme Centre for Demographic Science at the University of Oxford, explained. “We know much less about the donor side, especially in the US, and prior studies have mostly focused on financial concerns.”

In the analysis, Roberts and investigators leveraged data from 600 US relatives of patients with kidney disease who completed the 2019 Families of Renal Patients Survey. In the survey, participants rated 14 considerations, including financial, health, and relational factors, which affected their willingness to be evaluated as living donors.

Older adults were less likely than younger respondents to report reduced willingness for financial reasons, while younger adults more often reported increased willingness based on match likelihood, current health, and knowledge of living donation. Older respondents more often indicated that their own health reduced willingness, and adults aged 40 to 59 most often cited negative effects on their family.

Women were more likely than men to report reduced willingness related to financial and recovery concerns. Asian or Pacific Islander and Black respondents more often reported reduced willingness due to financial issues and the surgery itself, while Hispanic and White respondents more often reported increased willingness related to extending the recipient’s life.

Greater willingness related to match likelihood, current health, the donor–recipient relationship, and the potential to extend the recipient’s life was associated with completing more donation-related actions. Lower willingness tied to general views on organ donation, surgery, or recovery was associated with completing fewer actions.

After adjustment for demographic factors and relationship to the patient, significant associations remained for match likelihood, current health, the donor-recipient relationship, the potential to extend the recipient’s life, and general views on organ donation.

“The findings really suggest that counseling centered around relational and health related motivations tend to really drive action,” said Roberts. “So prior to evaluation, it would be important to explore donor-recipient relationships and acknowledge that, you know, interpersonal closeness might be a motivator for a lot of donors.”

Roberts MK, Ryan-Claytor C, Salim Z, Kirk JM, Rowe-Nicholls I, Daw J. Factors influencing willingness to pursue living kidney donation among relatives of patients with kidney disease in the United States. 

. Published online February 9, 2026. doi:

https://doi.org/10.1186/s12882-026-04806-3

90,000 people are waiting for a kidney. Here’s one way to get them a kidney faster. - UNOS. UNOS. Published January 27, 2025. 

https://unos.org/news/90000-people-are-waiting-for-a-kidney-heres-one-way-to-get-them-a-kidney-faster/

Videos

Survey of 600 US relatives finds donor–recipient closeness and expected life extension drive living kidney donation more than financial concerns.

Donor–Recipient Closeness, Perceived Life Extension Drive Living Kidney Donation Decisions, With Mary Roberts, PhD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

The First Interoperable Implanted CGM: The Eversense 365 and Twiist Insulin Pump

On February 16, 2026, parent companies Sequel Med Tech and Senseonics announced and launched a combination of the Twiist automated insulin delivery system and the Eversense 365, the first and only 1-year implantable continuous glucose monitor (CGM). This interoperability opens many doors for patients currently using the Eversense 365 for type 1 diabetes (T1D).

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the announcement and its implications for patients seeking lower-maintenance CGM options.

Check out the full episode on implantable insulin pumps and interoperability 

In this segment, the hosts turn their attention to the full commercial launch of the Eversense 365 CGM system integrated with the Twiist insulin pump, marking the first officially available pump partnership for the one-year implantable CGM. While an early release phase had already begun, the system is now broadly accessible, representing a meaningful expansion in diabetes technology options. The discussion situates this development within the broader theme of patient-centered device selection, underscoring that no single pump or sensor is optimal for all individuals with diabetes.

A central focus of the conversation is the clinical and experiential value of the Eversense 365 system. Unlike traditional transcutaneous CGMs requiring replacement every 7 to 15 days, the implantable sensor remains in place for up to one year, eliminating the recurring burden of frequent insertions and the variability often associated with “day one” sensor performance. Although initial calibrations are required, ongoing calibration frequency has been reduced to approximately once weekly, which the hosts describe as a manageable tradeoff for many patients. Importantly, after the early calibration phase, users no longer experience routine warm-up periods with each new sensor cycle.

The removable external transmitter is highlighted as a distinguishing feature. Because it sits atop the skin and can be detached temporarily, users can remove it during activities or simply take a break from wearing visible hardware, then reattach it to obtain readings. This flexibility may appeal to patients seeking intermittent device-free intervals without sacrificing long-term sensor continuity.

Accuracy and reliability are also emphasized. The hosts note strong performance metrics and specifically reference the absence of “pressure lows,” a phenomenon observed with some interstitial CGMs when external compression affects glucose readings. For individuals with skin sensitivity, adhesion challenges, or recurrent accuracy concerns related to sensor placement, the implantable system may offer a clinically meaningful alternative.

Finally, Isaacs and Bellini reflect on the broader implications of pump integration. Previously, lthe ack of pump connectivity limited adoption among patients committed to automated insulin delivery systems. With Eversense now communicating directly with a commercial pump, the potential user base may expand. The hosts conclude by expressing interest in whether additional pump manufacturers will pursue similar collaborations, suggesting that this milestone may catalyze greater interoperability and reinforce the importance of individualized, choice-driven diabetes technology strategies.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Senseonics. Sequel Med Tech and Senseonics Launch Transformative Combination of twiist and Eversense 365. February 19, 2026. Accessed February 23, 2026. 

https://www.senseonics.com/investor-relations/news-releases/2026/02-19-2026-130316928

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent release of the Eversense 365 by Sequel Medtech and Senseonics, paired with the Twiist insulin pump.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Topline data from the phase 3 PROSERA trial indicate that seralutinib, an investigational inhaled tyrosine kinase inhibitor, did not meet its prespecified primary efficacy threshold in 

(PAH), despite achieving nominal statistical significance on 6-minute walk distance (6MWD) at 24 weeks and higher efficacy in patients with intermediate and high-risk PAH.¹ 

“While we are disappointed to have narrowly missed the stringent prespecified statistical threshold for our primary endpoint, the result still clears the traditional 0.05 p-value, and we believe these data clearly demonstrate seralutinib is an active drug in patients with PAH,” Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio, said in a statement.

According to Gossamer Bio, the randomized, double-blind, placebo-controlled PROSERA study enrolled 390 patients with World Health Organization (WHO) functional class II or III PAH receiving background therapy.¹ Patients were randomized to seralutinib (n = 197) or placebo (n = 193) for up to 48 weeks. At week 24, the placebo-adjusted Hodges-Lehmann median difference in 6MWD was +13.3 meters (

= .0320), which did not meet the prespecified alpha threshold of 0.025 for the primary endpoint.¹ Because the primary endpoint was not met at the adjusted alpha level, secondary endpoint p values are considered nominal.

Median change from baseline in 6MWD was +28.2 meters in the seralutinib group and +13.5 meters in the placebo group at week 24.¹ In prespecified patients with intermediate- and high-risk PAH (REVEAL Lite 2 score ≥6; n = 234), the placebo-adjusted improvement was +20.0 meters (

 = .0207), an efficacy signal that was consistent with data seen from the phase 2 TORREY trial.

 Changes in N-terminal pro–B-type natriuretic peptide (NT-proBNP) at week 24 favored seralutinib (estimated location shift −120.4 ng/L; 

 = .0002), and other secondary measures—including clinical improvement and ≥1-point REVEAL Lite 2 score reduction—also numerically favored active treatment.¹ Time-to-clinical worsening hazard ratio was 0.744 (

“We are also pleased by the clinically meaningful improvements observed in intermediate- and high-risk patients who are at an increased risk of significant morbidity and mortality events and represent a population with a high unmet need. From a clinical development perspective, this is not a narrow or exploratory finding. Seralutinib has once again demonstrated a statistically robust and clinically meaningful signal in higher‑risk patients, consistent with the TORREY Study, which is a clearly defined and readily identifiable population. This finding is compelling on its own,” Hasnain said.

Seralutinib is an inhaled inhibitor of platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT, pathways implicated in vascular proliferation and remodeling.

 Unlike established PAH therapies, which primarily target vasodilation, seralutinib is designed to address proliferative and inflammatory mechanisms. Phase 2 data from the TORREY study previously demonstrated improvements in pulmonary vascular resistance and exploratory clinical endpoints which supported advancement to phase 3 evaluation.

 Inhaled tyrosine kinase inhibitor (PDGFR, CSF1R, c-KIT)

 PROSERA, phase 3, randomized, placebo-controlled (n = 390)¹

 Placebo-adjusted 6MWD +13.3 m at Week 24 (

 Transaminase elevations ≥3× ULN in 13% vs 1% with placebo¹

 Investigational; sponsor plans FDA discussion¹

Seralutinib was generally well tolerated. Treatment-emergent adverse events (TEAEs) occurred in 86.5% of patients receiving seralutinib and 80.5% receiving placebo.¹ Serious adverse events occurred in 16.0% and 18.9%, respectively. Transaminase elevations ≥3 times the upper limit of normal were reported in 13% of seralutinib-treated patients versus 1% with placebo.¹ Cough was the most frequent AE (37.0%).

PAH remains a progressive and life-threatening condition characterized by pulmonary vascular remodeling and right ventricular failure.

 Contemporary treatment algorithms emphasize risk stratification and early combination therapy with endothelin receptor antagonists, phosphodiesterase-5 inhibitors or soluble guanylate cyclase stimulators, and prostacyclin pathway agents. Despite therapeutic advances, morbidity and mortality remain substantial, particularly among intermediate- and high-risk patients. Hasnain stressed that the PROSERA population reflects the difficult-to-treat reality in contemporary practice: 55% were receiving triple or quadruple background therapy and 61% were on prostacyclin treatment.¹ 

Although the primary endpoint narrowly missed the prespecified statistical threshold, the nominally positive 6MWD result and consistent signal in higher-risk subgroups suggest biological activity. Gossamer Bio has indicated plans to meet with the United States Food and Drug Administration (FDA) to discuss a potential path forward.¹ 

Gossamer Bio. Gossamer Bio announces topline results from the Phase 3 PROSERA study evaluating seralutinib in pulmonary arterial hypertension. February 23, 2026. Accessed February 23, 2026. https://www.gossamerbio.com/news-releases/news-release-details/gossamer-bio-announces-topline-results-phase-3-prosera-study

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 

. 2022;43(38). doi: 10.1093/eurheartj/ehac237

Frantz RP, McLaughlin VV, Sahay S, et al. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial. 

. 2024;12(7):523-534. doi: 10.1016/S2213-2600(24)00072-9

Phase 3 PROSERA evaluated inhaled seralutinib added to background therapy in WHO FC II–III PAH. The study narrowly missed its prespecified alpha (0.025) for the 24-week 6MWD primary endpoint despite nominal significance (+13.3 m; P=.032). A stronger, consistent signal emerged in intermediate/high-risk patients (REVEAL Lite 2 ≥6; +20.0 m; P=.0207) alongside favorable NT-proBNP shifts. Safety was generally acceptable, but transaminase elevations were more frequent. Regulatory discussions are planned.

Seralutinib did improve 6-minute walk times and biomarkers, especially in patients with higher-risk disease.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

PROSERA: Seralutinib Falls Short in Pulmonary Arterial Hypertension Phase 3 Trial

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Luspatercept (Reblozyl®) met primary endpoints in both non-transfusion-dependent (NTD) and transfusion-dependent (TD) adults with 

 in the first registrational phase 2 trial in this population.

Bristol Myers Squibb announced the positive top-line results on February 23, 2026, including luspatercept increased hemoglobin in NTD and reduced transfusion burden in TD, along with meeting all secondary endpoints and exhibiting a consistent safety profile.

“These positive data further support the potential of Reblozyl for patients around the world,” said Cristian Massacesi, MD, Executive Vice President, Chief Medical Officer, and Head of Development at Bristol Myers Squibb, in a statement. “This is the first and only registrational Phase 2 trial specifically designed to address the needs of patients, especially in China, with alpha-thalassemia, a lifelong disease with limited treatment options and the potential for serious long-term complications.”

Alpha-thalassemia is a hereditary blood disorder characterized by reduced or absent alpha-globin chain production, leading to chronic anemia. Patients with transfusion-dependent disease often require lifelong RBC transfusions, which are associated with iron overload and other complications. Therapeutic options for non–transfusion-dependent alpha-thalassemia remain limited.

Luspatercept is a recombinant fusion protein that binds select transforming growth factor-β superfamily ligands, inhibiting SMAD2/3 signaling and promoting late-stage RBC maturation. In the United States, Reblozyl is approved by the US Food and Drug Administration for anemia in adults with beta-thalassemia who require regular RBC transfusions and for certain lower-risk myelodysplastic syndromes. It is not currently approved for alpha-thalassemia.

In the NTD cohort, luspatercept demonstrated a statistically significant and clinically meaningful increase in hemoglobin. The primary endpoint was a ≥1 g/dL increase from baseline in mean hemoglobin over a continuous 12-week interval from Week 13 to Week 24 in the absence of red blood cell (RBC) transfusion.

In the TD cohort, luspatercept demonstrated a statistically significant and clinically meaningful reduction in RBC transfusion burden. The primary endpoint was a ≥50% reduction from baseline in transfusion burden with a ≥2-unit reduction during any continuous 12 weeks between Week 13 and Week 48 compared with the 12-week interval before the first dose.

The ongoing study is evaluating luspatercept plus best supportive care versus placebo in adults and adolescents with alpha-thalassemia, including both TD and NTD cohorts. The adolescent cohorts remain ongoing. Data from the trial are expected to be presented at an upcoming medical congress and will be discussed with the Center for Drug Evaluation in China.

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia. Bms.com. Published 2020. Accessed February 23, 2026. 

https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Announces-Positive-Top-Line-Results-from-Registrational-Phase-2-Study-of-Luspatercept-in-Adults-with-Alpha--Thalassemia/default.aspx

Patel B, Moosavi L. Luspatercept. PubMed. Published 2023. 

https://www.ncbi.nlm.nih.gov/books/NBK560635/

Positive top-line results from a registrational phase 2 trial showed luspatercept met primary endpoints in adults with alpha-thalassemia across non–transfusion-dependent and transfusion-dependent cohorts. Non–transfusion-dependent patients achieved a statistically significant, clinically meaningful hemoglobin rise without interim RBC transfusions, while transfusion-dependent patients had substantial reductions in transfusion burden. All secondary endpoints were met with a safety profile consistent with prior experience. The trial includes best supportive care and placebo comparators, with adolescent cohorts ongoing and planned regulatory discussions in China.

Luspatercept met primary endpoints in transfusion-dependent and non–transfusion-dependent alpha-thalassemia.

Hematology

Luspatercept Meets Primary Endpoints in Phase 2 Alpha-Thalassemia Trial

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This approval of the Allurion Gastric Balloon System, incorporating the Allurion Smart Capsule, is indicated for weight loss management for those with obesity.

FDA News

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

FDA Grants Premarket Approval to Allurion Gastric Balloon System for Weight Loss

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The phase 3 REDEFINE 4 trial saw CagriSema achieve 23% weight loss, but fail to demonstrate noninferiority to tirzepatide in patients with overweight or obesity.

CagriSema Demonstrates Weight Loss, Fails to Achieve Primary Endpoint Compared to Tirzepatide

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The FDA has granted both designations to TSRA-196, an in vivo gene editing program from Tessera Therapeutics, for the treatment of PiZZ alpha-1 antitrypsin deficiency.

Alpha-1 antitrypsin deficiency

TSRA-196 Gets FDA Fast Track, Orphan Drug Designations for AATD

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA clears iloperidone metabolite, milsaperidone, for acute bipolar I disorder and schizophrenia, expanding treatment options.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Bipolar Disorder

The HCPLive bipolar disorder page is a resource for medical news and expert insights on BPD. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for bipolar disease, and more.

FDA Approves Milsaperidone for Acute Bipolar I Disorder, Schizophrenia

Podcasts

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent release of Eli Lilly's Zepbound as an injectable with the KwikPen.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: Launch of the Zepbound KwikPen

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

New studies reveal potential benefits of alfagimor in reducing fatigue and pruritus, highlighting its role in second-line therapy for patients.

New Fatigue Signals From Elafibranor: Results From the ELATIVE Phase III Trial

In this episode, experts delve into the limited treatment options to address the symptom of fatigue in patients with primary biliary cholangitis. They highlight how small changes, like regular sleep schedules and exercise, can improve fatigue.

Addressing Fatigue: Traditional Management Outside Primary Therapy

The CUPID-C randomized clinical trial confirmed CUPID-A results, with dupilumab significantly reducing urticaria in anti-IgE–naive individuals with CSU.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Dupilumab Reduces Urticaria Activity in Anti-IgE–Naive Patients with CSU

Levine discusses 24-hour adverse event resolution, retreatment questions, and scalability of supervised psilocybin therapy for treatment-resistant depression.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

COMP360 Safety Data in Phase 3 TRD Trials, With Steve Levine, MD

Ron Vender, MD, is a dermatologist in Hamilton, Ontario, and is the founder and director of Dermatrials Research Incorporated and Venderm Consulting Inc. He is also an associate clinical professor at McMaster University in the Department of Medicine, Division of Dermatology.

This interview segment highlights additional points on bimekizumab and psoriasis related to patient-reported outcomes (PROs) in the 3 year BE RADIANT study.

Latest News

HCPLive 5 Stories in Under 5: Week of 02/15

Donor–Recipient Closeness, Perceived Life Extension Drive Living Kidney Donation Decisions, With Mary Roberts, PhD

The First Interoperable Implanted CGM: The Eversense 365 and Twiist Insulin Pump

PROSERA: Seralutinib Falls Short in Pulmonary Arterial Hypertension Phase 3 Trial

Luspatercept Meets Primary Endpoints in Phase 2 Alpha-Thalassemia Trial